A French pharmaceutical company has announced a partnership with a US biotech company to develop a monoclonal antibody drug for COVID-19

2022-07-02 0 By

French pharmaceutical company Cenexi announced on Tuesday that it has reached an agreement with US biotech company Humanigen to manufacture Lenzilumab in France, Le Figaro reported.This is a monoclonal antibody being studied for COVID-19, designed to prevent and treat “cytokine shock” or “cytokine storm,” which causes an uncontrolled inflammatory response and appears to play a key role in patients with severe COVID-19.Both companies are currently in the process of registering with European and French health authorities.